CVE:COT - Cotinga Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$0.10 0.00 (0.00 %)
(As of 01/22/2019 08:00 AM ET)
Previous CloseC$0.10
Today's RangeC$0.10 - C$0.10
52-Week RangeC$0.05 - C$1.02
Volume4,770 shs
Average Volume115,690 shs
Market CapitalizationN/A
P/E Ratio-0.44
Dividend YieldN/A
BetaN/A
Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, a clinical stage oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.

Receive COT News and Ratings via Email

Sign-up to receive the latest news and ratings for COT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+1-519-8585157

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC($0.06) per share

Profitability

Miscellaneous

EmployeesN/A
OptionableOptionable

Cotinga Pharmaceuticals (CVE:COT) Frequently Asked Questions

What is Cotinga Pharmaceuticals' stock symbol?

Cotinga Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "COT."

When is Cotinga Pharmaceuticals' next earnings date?

Cotinga Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, April 2nd 2019. View Earnings Estimates for Cotinga Pharmaceuticals.

Has Cotinga Pharmaceuticals been receiving favorable news coverage?

Media stories about COT stock have trended very positive this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cotinga Pharmaceuticals earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are some of Cotinga Pharmaceuticals' key competitors?

Who are Cotinga Pharmaceuticals' key executives?

Cotinga Pharmaceuticals' management team includes the folowing people:
  • Ms. Alison D. Silva, Chief Exec. Officer, Pres and Director
  • Mr. Victor Hugo, Chief Financial Officer (Age 51)
  • Ms. Debi Sanderson MBA, Director of Resourcing & Operations
  • Dr. Richard T. Ho, Chief Scientific Officer (Age 56)
  • Mr. Paul Papi, VP of Investor Relations

How do I buy shares of Cotinga Pharmaceuticals?

Shares of COT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cotinga Pharmaceuticals' stock price today?

One share of COT stock can currently be purchased for approximately C$0.10.

What is Cotinga Pharmaceuticals' official website?

The official website for Cotinga Pharmaceuticals is http://cotingapharma.com.

How can I contact Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals' mailing address is 100 Collip Cir Suite 230B, LONDON, ON N6G 4X8, Canada. The company can be reached via phone at +1-519-8585157.


MarketBeat Community Rating for Cotinga Pharmaceuticals (CVE COT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Cotinga Pharmaceuticals and other stocks. Vote "Outperform" if you believe COT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Featured Article: Rule of 72

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel